Literature DB >> 25555148

Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC-MS/MS quantification.

Leah C Jimmerson1, Michelle L Ray2, Lane R Bushman3, Peter L Anderson4, Brandon Klein5, Joseph E Rower6, Jia-Hua Zheng7, Jennifer J Kiser8.   

Abstract

Ribavirin (RBV) is a nucleoside analog used to treat a variety of DNA and RNA viruses. RBV undergoes intracellular phosphorylation to a mono- (MP), di- (DP), and triphosphate (TP). The phosphorylated forms have been associated with the mechanisms of antiviral effect observed in vitro, but the intracellular pharmacology of the drug has not been well characterized in vivo. A highly sensitive LC-MS/MS method was developed and validated for the determination of intracellular RBV MP, DP, and TP in multiple cell matrix types. For this method, the individual MP, DP, and TP fractions were isolated from lysed intracellular matrix using strong anion exchange solid phase extraction, dephosphorylated to parent RBV, desalted and concentrated and quantified using LC-MS/MS. The method utilized a stable labeled internal standard (RBV-(13)C5) which facilitated accuracy (% deviation within ±15%) and precision (coefficient of variation of ≤15%). The quantifiable linear range for the assay was 0.50 to 200 pmol/sample. The method was applied to the measurement of RBV MP, DP, and TP in human peripheral blood mononuclear cells (PBMC), red blood cells (RBC), and dried blood spot (DBS) samples obtained from patients taking RBV for the treatment of chronic Hepatitis C virus infection.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Analytical methods; Clinical pharmacology; Dried blood spots; Intracellular pharmacology; LC–MS/MS; Ribavirin triphosphate

Mesh:

Substances:

Year:  2014        PMID: 25555148      PMCID: PMC4297558          DOI: 10.1016/j.jchromb.2014.11.032

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  17 in total

Review 1.  Mechanism of action of ribavirin in the combination treatment of chronic HCV infection.

Authors:  Johnson Y N Lau; Robert C Tam; T Jake Liang; Zhi Hong
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

2.  Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter.

Authors:  S D Patil; L Y Ngo; P Glue; J D Unadkat
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

Review 3.  Ribavirin's antiviral mechanism of action: lethal mutagenesis?

Authors:  Shane Crotty; Craig Cameron; Raul Andino
Journal:  J Mol Med (Berl)       Date:  2001-12-04       Impact factor: 4.599

4.  High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes.

Authors:  M Homma; A L Jayewardene; J Gambertoglio; F Aweeka
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells.

Authors:  Tracy King; Lane Bushman; Jennifer Kiser; Peter L Anderson; Michelle Ray; Thomas Delahunty; Courtney V Fletcher
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-07-07       Impact factor: 3.205

6.  LC-MS/MS method for simultaneous determination of viramidine and ribavirin levels in monkey red blood cells.

Authors:  Li-Tain Yeh; Mai Nguyen; Sohelia Dadgostari; Wei Bu; Chin-Chung Lin
Journal:  J Pharm Biomed Anal       Date:  2006-10-06       Impact factor: 3.935

7.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

Review 8.  Mechanism of action of interferon and ribavirin in treatment of hepatitis C.

Authors:  Jordan J Feld; Jay H Hoofnagle
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

9.  Effects of ribavirin on red blood cells.

Authors:  P G Canonico; M D Kastello; C T Spears; J R Brown; E A Jackson; D E Jenkins
Journal:  Toxicol Appl Pharmacol       Date:  1984-06-30       Impact factor: 4.219

10.  Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin.

Authors:  D Maag; C Castro; Z Hong; C E Cameron
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157

View more
  7 in total

1.  Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients.

Authors:  Edward J Fuchs; Jennifer J Kiser; Craig W Hendrix; Mark Sulkowski; Christine Radebaugh; Lane Bushman; Michelle L Ray; Adriana Andrade
Journal:  J Antimicrob Chemother       Date:  2016-02-10       Impact factor: 5.790

Review 2.  Direct and indirect quantification of phosphate metabolites of nucleoside analogs in biological samples.

Authors:  Nagsen Gautam; Jawaher Abdullah Alamoudi; Sushil Kumar; Yazen Alnouti
Journal:  J Pharm Biomed Anal       Date:  2019-10-03       Impact factor: 3.935

3.  A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells.

Authors:  Leah C Jimmerson; Lane R Bushman; Michelle L Ray; Peter L Anderson; Jennifer J Kiser
Journal:  Pharm Res       Date:  2016-09-15       Impact factor: 4.200

4.  Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.

Authors:  Liviawati S Wu; Joseph E Rower; James R Burton; Peter L Anderson; Kyle P Hammond; Fafa Baouchi-Mokrane; Gregory T Everson; Thomas J Urban; David Z D'Argenio; Jennifer J Kiser
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

5.  Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.

Authors:  Joseph E Rower; Eric G Meissner; Leah C Jimmerson; Anu Osinusi; Zayani Sims; Tess Petersen; Lane R Bushman; Pamela Wolfe; John G McHutchison; Shyamasundaran Kottilil; Jennifer J Kiser
Journal:  J Antimicrob Chemother       Date:  2015-05-13       Impact factor: 5.790

6.  Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells.

Authors:  Joseph E Rower; Leah C Jimmerson; Xinhui Chen; Jia-Hua Zheng; Ariel Hodara; Lane R Bushman; Peter L Anderson; Jennifer J Kiser
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

7.  Challenges and stepwise fit-for-purpose optimization for bioanalyses of remdesivir metabolites nucleotide monophosphate and triphosphate in mouse tissues using LC-MS/MS.

Authors:  Wenjuan Hu; Lu Chang; Changqiang Ke; Yuanchao Xie; Jingshan Shen; Bo Tan; Jia Liu
Journal:  J Pharm Biomed Anal       Date:  2020-11-30       Impact factor: 3.935

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.